Actuate Therapeutics Inc
NASDAQ: ACTU0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel Schmitt
- Employees
- 10
- Headquarters
- Fort Worth, United States
- IPO year
- 2024
- Market cap
- $46.7M
- Website
- https://actuatetherapeutics.com
Loading ACTU…
Loading profile data…Frequently asked questions about ACTU
What does Actuate Therapeutics Inc (ACTU) do?
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is bei...
Where does ACTU trade?
Actuate Therapeutics Inc (ACTU) trades on the NASDAQ Global Market.
What sector is ACTU in?
Actuate Therapeutics Inc (ACTU) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Actuate Therapeutics Inc?
Daniel Schmitt is the chief executive officer of Actuate Therapeutics Inc (ACTU).
Where is Actuate Therapeutics Inc headquartered?
Actuate Therapeutics Inc is headquartered in United States.
Does ACTU pay a dividend?
Actuate Therapeutics Inc (ACTU) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ACTU go public?
Actuate Therapeutics Inc (ACTU) completed its initial public offering in 2024.